Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer.

Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjäkoski K, Kallioniemi A, Kilpivaara O, Mannermaa A, Kosma VM, Uusitupa M, Eskelinen M, Kataja V, Aittomäki K, von Smitten K, Heikkilä P, Lukas J, Holli K, Bartkova J, Blomqvist C, Bartek J, Nevanlinna H.

Nat Genet. 2008 Jul;40(7):844-53. doi: 10.1038/ng.155. Epub 2008 May 30.

PMID:
18511948
2.

NQO1 expression correlates inversely with NFκB activation in human breast cancer.

Jamshidi M, Bartkova J, Greco D, Tommiska J, Fagerholm R, Aittomäki K, Mattson J, Villman K, Vrtel R, Lukas J, Heikkilä P, Blomqvist C, Bartek J, Nevanlinna H.

Breast Cancer Res Treat. 2012 Apr;132(3):955-68. doi: 10.1007/s10549-011-1629-5. Epub 2011 Jun 25.

PMID:
21706157
3.

NAD(P)H:quinone oxidoreductase 1 Pro187Ser polymorphism and expression do not cosegregate with clinico-pathological characteristics of human mammary tumors.

Hubackova M, Vaclavikova R, Mrhalova M, Kubackova K, Kodet R, Gut I, Soucek P.

Pharmacogenet Genomics. 2009 Jul;19(7):505-12. doi: 10.1097/FPC.0b013e32832cf9cf.

PMID:
19494791
4.

DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma.

Cabello CM, Lamore SD, Bair WB 3rd, Davis AL, Azimian SM, Wondrak GT.

Free Radic Res. 2011 Mar;45(3):276-92. doi: 10.3109/10715762.2010.526766. Epub 2010 Nov 1.

5.

Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy.

Jamieson D, Cresti N, Bray J, Sludden J, Griffin MJ, Hawsawi NM, Famie E, Mould EV, Verrill MW, May FE, Boddy AV.

Pharmacogenet Genomics. 2011 Dec;21(12):808-19. doi: 10.1097/FPC.0b013e32834b6918.

PMID:
21946896
6.

Clinical significance of NQO1 C609T polymorphisms after postoperative radiation therapy in completely resected non-small cell lung cancer.

Song SY, Jeong SY, Park HJ, Park SI, Kim DK, Kim YH, Shin SS, Lee SW, Ahn SD, Kim JH, Lee JS, Choi EK.

Lung Cancer. 2010 May;68(2):278-82. doi: 10.1016/j.lungcan.2009.06.009.

PMID:
19596483
7.

Clinical significance of a NAD(P)H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C.

Fleming RA, Drees J, Loggie BW, Russell GB, Geisinger KR, Morris RT, Sachs D, McQuellon RP.

Pharmacogenetics. 2002 Jan;12(1):31-7.

PMID:
11773862
8.

ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism.

Cleton-Jansen AM, van Eijk R, Lombaerts M, Schmidt MK, Van't Veer LJ, Philippo K, Zimmerman RM, Peterse JL, Smit VT, van Wezel T, Cornelisse CJ.

BMC Cancer. 2008 Apr 16;8:105. doi: 10.1186/1471-2407-8-105.

9.
10.

Overexpression of NAD(P)H:quinone oxidoreductase 1 (NQO1) and genomic gain of the NQO1 locus modulates breast cancer cell sensitivity to quinones.

Glorieux C, Sandoval JM, Dejeans N, Ameye G, Poirel HA, Verrax J, Calderon PB.

Life Sci. 2016 Jan 15;145:57-65. doi: 10.1016/j.lfs.2015.12.017. Epub 2015 Dec 10.

PMID:
26687450
11.

Increased tumor necrosis factor-alpha sensitivity of MCF-7 cells transfected with NAD(P)H:quinone reductase.

Siemankowski LM, Morreale J, Butts BD, Briehl MM.

Cancer Res. 2000 Jul 1;60(13):3638-44.

12.
13.

Oral contraceptive use and breast cancer risk: modification by NAD(P)H:quinone oxoreductase (NQO1) genetic polymorphisms.

Fowke JH, Shu XO, Dai Q, Jin F, Cai Q, Gao YT, Zheng W.

Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1308-15.

14.

NAD(P)H:quinone oxidoreductase 1 (NQO1) P187S polymorphism and prostate cancer risk in Caucasians.

Stoehr CG, Nolte E, Wach S, Wieland WF, Hofstaedter F, Hartmann A, Stoehr R.

Int J Mol Sci. 2012;13(9):10959-69. doi: 10.3390/ijms130910959. Epub 2012 Jul 26.

15.

Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1.

Siegel D, McGuinness SM, Winski SL, Ross D.

Pharmacogenetics. 1999 Feb;9(1):113-21. Erratum in: Pharmacogenetics 1999 Jun;9(3):419.

PMID:
10208650
16.

NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C.

Basu S, Brown JE, Flannigan GM, Gill JH, Loadman PM, Martin SW, Naylor B, Puri R, Scally AJ, Seargent JM, Shah T, Phillips RM.

Int J Oncol. 2004 Oct;25(4):921-7.

PMID:
15375541
17.

NQO1 C609T polymorphism in distinct entities of pediatric hematologic neoplasms.

Kracht T, Schrappe M, Strehl S, Reiter A, Elsner HA, Trka J, Cario G, Viehmann S, Harbott J, Borkhardt A, Metzler M, Langer T, Repp R, Marschalek R, Welte K, Haas OA, Stanulla M.

Haematologica. 2004 Dec;89(12):1492-7.

18.

Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy.

Geng R, Chen Z, Zhao X, Qiu L, Liu X, Liu R, Guo W, He G, Li J, Zhu X.

PLoS One. 2014 Dec 29;9(12):e116027. doi: 10.1371/journal.pone.0116027. eCollection 2014.

19.

Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients--potential differential effects by radiotherapy?

Seibold P, Hall P, Schoof N, Nevanlinna H, Heikkinen T, Benner A, Liu J, Schmezer P, Popanda O, Flesch-Janys D, Chang-Claude J.

Breast. 2013 Oct;22(5):817-23. doi: 10.1016/j.breast.2013.02.008. Epub 2013 Mar 13.

PMID:
23489758
20.

Increased levels of NAD(P)H: quinone oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: A potential biomarker of early damage in the pancreas.

Lyn-Cook BD, Yan-Sanders Y, Moore S, Taylor S, Word B, Hammons GJ.

Cell Biol Toxicol. 2006 Mar;22(2):73-80. Epub 2006 Mar 9.

PMID:
16532285

Supplemental Content

Support Center